213 related articles for article (PubMed ID: 15788675)
1. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
Nutt CL; Betensky RA; Brower MA; Batchelor TT; Louis DN; Stemmer-Rachamimov AO
Clin Cancer Res; 2005 Mar; 11(6):2258-64. PubMed ID: 15788675
[TBL] [Abstract][Full Text] [Related]
2. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
[TBL] [Abstract][Full Text] [Related]
3. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
Nutt CL; Mani DR; Betensky RA; Tamayo P; Cairncross JG; Ladd C; Pohl U; Hartmann C; McLaughlin ME; Batchelor TT; Black PM; von Deimling A; Pomeroy SL; Golub TR; Louis DN
Cancer Res; 2003 Apr; 63(7):1602-7. PubMed ID: 12670911
[TBL] [Abstract][Full Text] [Related]
4. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
Horbinski C; Wang G; Wiley CA
Int J Clin Exp Pathol; 2010 Jan; 3(3):226-37. PubMed ID: 20224722
[TBL] [Abstract][Full Text] [Related]
5. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas.
Soichi O; Masanori N; Hideo T; Kazunori A; Nobuya I; Jun-ichi K
Neurosurgery; 2007 Apr; 60(4):707-14; discussion 714. PubMed ID: 17415208
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas.
Neder L; Marie SK; Carlotti CG; Gabbai AA; Rosemberg S; Malheiros SM; Siqueira RP; Oba-Shinjo SM; Uno M; Aguiar PH; Miura F; Chammas R; Colli BO; Silva WA; Zago MA
Brain Pathol; 2004 Oct; 14(4):399-405. PubMed ID: 15605987
[TBL] [Abstract][Full Text] [Related]
8. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
Pelloski CE; Mahajan A; Maor M; Chang EL; Woo S; Gilbert M; Colman H; Yang H; Ledoux A; Blair H; Passe S; Jenkins RB; Aldape KD
Clin Cancer Res; 2005 May; 11(9):3326-34. PubMed ID: 15867231
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
Antonelli M; Buttarelli FR; Arcella A; Nobusawa S; Donofrio V; Oghaki H; Giangaspero F
J Neurooncol; 2010 Sep; 99(2):209-15. PubMed ID: 20174854
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
[TBL] [Abstract][Full Text] [Related]
11. Protein and mRNA levels of YKL-40 in high-grade glioma.
Kazakova MH; Staneva DN; Koev IG; Staikov DG; Mateva N; Timonov PT; Miloshev GA; Sarafian VS
Folia Biol (Praha); 2014; 60(6):261-7. PubMed ID: 25629266
[TBL] [Abstract][Full Text] [Related]
12. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
Iwamoto FM; Hottinger AF; Karimi S; Riedel E; Dantis J; Jahdi M; Panageas KS; Lassman AB; Abrey LE; Fleisher M; DeAngelis LM; Holland EC; Hormigo A
Neuro Oncol; 2011 Nov; 13(11):1244-51. PubMed ID: 21831900
[TBL] [Abstract][Full Text] [Related]
13. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.
Cassoni P; Senetta R; Castellano I; Ortolan E; Bosco M; Magnani I; Ducati A
Am J Surg Pathol; 2007 May; 31(5):760-9. PubMed ID: 17460461
[TBL] [Abstract][Full Text] [Related]
14. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis.
Shirahata M; Iwao-Koizumi K; Saito S; Ueno N; Oda M; Hashimoto N; Takahashi JA; Kato K
Clin Cancer Res; 2007 Dec; 13(24):7341-56. PubMed ID: 18094416
[TBL] [Abstract][Full Text] [Related]
15. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.
Tanwar MK; Gilbert MR; Holland EC
Cancer Res; 2002 Aug; 62(15):4364-8. PubMed ID: 12154041
[TBL] [Abstract][Full Text] [Related]
16. Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma.
Luider TM; Kros JM; Sillevis Smitt PA; van den Bent MJ; Vecht CJ
Electrophoresis; 1999; 20(4-5):1087-91. PubMed ID: 10344289
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma.
Gimenez M; Marie SK; Oba-Shinjo S; Uno M; Izumi C; Oliveira JB; Rosa JC
BMC Cancer; 2015 Jun; 15():481. PubMed ID: 26108672
[TBL] [Abstract][Full Text] [Related]
18. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
Gupta M; Djalilvand A; Brat DJ
Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
[TBL] [Abstract][Full Text] [Related]
19. Association between YKL-40 and adult primary astrocytoma.
Zhang W; Kawanishi M; Miyake K; Kagawa M; Kawai N; Murao K; Nishiyama A; Fei Z; Zhang X; Tamiya T
Cancer; 2010 Jun; 116(11):2688-97. PubMed ID: 20499402
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.
Kim SH; Das K; Noreen S; Coffman F; Hameed M
World J Surg Oncol; 2007 Feb; 5():17. PubMed ID: 17286869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
